These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1366 related articles for article (PubMed ID: 22945360)

  • 1. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
    Meier JJ
    Nat Rev Endocrinol; 2012 Dec; 8(12):728-42. PubMed ID: 22945360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR; Monnier L; Bolli GB
    Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.
    Derosa G; Maffioli P
    Curr Clin Pharmacol; 2012 Aug; 7(3):214-28. PubMed ID: 22432846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
    González C; Beruto V; Keller G; Santoro S; Di Girolamo G
    Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glucagon-like peptide 1 (GLP-1)].
    Parhofer KG
    MMW Fortschr Med; 2007 Jun; 149(25-26):41-3. PubMed ID: 17713050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
    Gallwitz B
    Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
    Christensen M; Knop FK
    Curr Diab Rep; 2010 Apr; 10(2):124-32. PubMed ID: 20425571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 based therapies: differential effects on fasting and postprandial glucose.
    Fineman MS; Cirincione BB; Maggs D; Diamant M
    Diabetes Obes Metab; 2012 Aug; 14(8):675-88. PubMed ID: 22233527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
    Drab SR
    Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
    Maselli DB; Camilleri M
    Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.